AU2016202513A1 - Composition - Google Patents

Composition

Info

Publication number
AU2016202513A1
AU2016202513A1 AU2016202513A AU2016202513A AU2016202513A1 AU 2016202513 A1 AU2016202513 A1 AU 2016202513A1 AU 2016202513 A AU2016202513 A AU 2016202513A AU 2016202513 A AU2016202513 A AU 2016202513A AU 2016202513 A1 AU2016202513 A1 AU 2016202513A1
Authority
AU
Australia
Prior art keywords
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2016202513A
Other versions
AU2016202513B2 (en
Inventor
Claire Louise AMBERY
Christopher David EDWARDS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/064139 external-priority patent/WO2013014052A1/en
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Priority to AU2016202513A priority Critical patent/AU2016202513B2/en
Publication of AU2016202513A1 publication Critical patent/AU2016202513A1/en
Application granted granted Critical
Publication of AU2016202513B2 publication Critical patent/AU2016202513B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2016202513A 2011-07-22 2016-04-20 Composition Ceased AU2016202513B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016202513A AU2016202513B2 (en) 2011-07-22 2016-04-20 Composition

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161510624P 2011-07-22 2011-07-22
US61/510,624 2011-07-22
PCT/EP2012/064139 WO2013014052A1 (en) 2011-07-22 2012-07-19 Composition
AU2012289042A AU2012289042A1 (en) 2011-07-22 2012-07-19 Composition
AU2016202513A AU2016202513B2 (en) 2011-07-22 2016-04-20 Composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2012289042A Division AU2012289042A1 (en) 2011-07-22 2012-07-19 Composition

Publications (2)

Publication Number Publication Date
AU2016202513A1 true AU2016202513A1 (en) 2016-05-12
AU2016202513B2 AU2016202513B2 (en) 2018-03-22

Family

ID=46581948

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012289042A Abandoned AU2012289042A1 (en) 2011-07-22 2012-07-19 Composition
AU2016202513A Ceased AU2016202513B2 (en) 2011-07-22 2016-04-20 Composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2012289042A Abandoned AU2012289042A1 (en) 2011-07-22 2012-07-19 Composition

Country Status (19)

Country Link
US (2) US10112946B2 (en)
EP (1) EP2734186B1 (en)
JP (1) JP2014520874A (en)
KR (1) KR101916928B1 (en)
CN (1) CN103841958A (en)
AU (2) AU2012289042A1 (en)
BR (1) BR112014001425A2 (en)
CA (1) CA2841361A1 (en)
CY (1) CY1120802T1 (en)
DK (1) DK2734186T3 (en)
ES (1) ES2693122T3 (en)
HR (1) HRP20181667T1 (en)
LT (1) LT2734186T (en)
PL (1) PL2734186T3 (en)
PT (1) PT2734186T (en)
RS (1) RS57995B1 (en)
RU (1) RU2631482C2 (en)
SI (1) SI2734186T1 (en)
WO (1) WO2013014052A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (en) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
LT2734186T (en) 2011-07-22 2018-12-10 Glaxosmithkline Llc Composition
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9428512B2 (en) 2012-11-20 2016-08-30 Glaxosmithkline Llc Compounds
ES2632448T3 (en) 2012-11-20 2017-09-13 Glaxosmithkline Llc New compounds
HUE13857477T2 (en) 2012-11-20 2018-05-28 Glaxosmithkline Llc Novel compounds

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (en) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
JP2003519232A (en) 2000-01-07 2003-06-17 ウニフェルジテーレ・インステリング・アントウェルペン Purine derivatives, their production and their use
CA2407594A1 (en) 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
CA2457468A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
RU2217159C1 (en) * 2002-03-18 2003-11-27 ООО "Содарм фарма" Solution for inhalation of pharmaceutical composition "glutovent" and method for treatment with its using
EP1348707B1 (en) 2002-03-28 2010-08-25 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
MXPA04010983A (en) 2002-05-06 2005-02-14 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis c virus infection.
US6713241B2 (en) 2002-08-09 2004-03-30 Eastman Kodak Company Thermally developable emulsions and imaging materials containing binder mixture
DK1539783T3 (en) 2002-08-21 2011-06-20 Einstein Coll Med Inhibitors of nucleoside phosphorylases and nucleosidases
NZ539064A (en) 2002-09-27 2007-09-28 Dainippon Sumitomo Pharma Co Novel adenine compound and use thereof
JP2007521296A (en) 2003-07-01 2007-08-02 メルク エンド カムパニー インコーポレーテッド Ophthalmic composition for the treatment of high intraocular pressure
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
ATE465742T1 (en) 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc TLR7 LIGANDS FOR TREATING HEPATITIS C
WO2005079195A2 (en) 2003-10-03 2005-09-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
JP4641526B2 (en) 2003-11-03 2011-03-02 グラクソ グループ リミテッド Fluid distribution device
ES2563952T3 (en) 2004-03-26 2016-03-16 Sumitomo Dainippon Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
JPWO2005092892A1 (en) 2004-03-26 2008-02-14 大日本住友製薬株式会社 8-Oxoadenine compounds
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
CA2566158A1 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
NZ540160A (en) 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
CA2615946A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
EP1945626B1 (en) 2005-08-25 2011-07-27 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
EA200800396A1 (en) 2005-09-02 2008-08-29 Пфайзер Инк. HYDROXYMEDIATED 1H-IMIDAZOPIRIDINES AND METHODS
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Novel adenine compound
WO2007034917A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034817A1 (en) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
JPWO2007034882A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
CN1947717B (en) 2005-10-14 2012-09-26 卓敏 Method for treating neuronal and non-neuronal pain
ES2374455T3 (en) 2006-02-17 2012-02-16 Pfizer Limited DERIVATIVES OF 3-DEAZAPURINZA AS MODULATORS OF TLR7.
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
EP2041135A4 (en) 2006-07-05 2010-12-01 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
TWI399377B (en) 2006-07-07 2013-06-21 Gilead Sciences Inc Modulators of toll-like receptor 7
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
WO2008101867A1 (en) 2007-02-19 2008-08-28 Smithkline Beecham Corporation Purine derivatives as immunomodulators
JP5329444B2 (en) 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ 9-Substituted-8-oxo-adenine compounds as TOLL-like receptor (TLR7) modulators
JP5480637B2 (en) 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ 9-Substituted-8-oxo-adenine compounds as TOLL-like receptor (TLR7) modulators
PE20081887A1 (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Novel adenine compound
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
AU2008271127C1 (en) 2007-06-29 2014-04-17 Gilead Sciences, Inc. Purine derivatives and their use as modulators of Toll-like receptor 7
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
BRPI0814939A2 (en) 2007-08-10 2015-01-27 Glaxosmithkline Llc CHEMICAL ENTITY, PHARMACEUTICAL COMPOSITION, AND METHOD FOR TREATING A VIRAL INFECTION IN A MAMMALIAN.
UY31531A1 (en) 2007-12-17 2009-08-03 SALTS DERIVED FROM 8-OXOADENINE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY AS TOLL TYPE RECEIVER MODULATORS (TLR)
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
JP2011530562A (en) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー Purine derivatives for the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (en) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
EP2326646B1 (en) 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
HUE033645T2 (en) 2008-08-11 2017-12-28 Glaxosmithkline Llc Novel adenine derivatives
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
WO2010083725A1 (en) 2009-01-20 2010-07-29 山东轩竹医药科技有限公司 Cephalosporin derivatives containing substituted nitrogen-containing fused heterocyclic ring
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
MX2012001524A (en) 2009-08-07 2012-02-29 Glaxosmithkline Biolog Sa Lipidated oxoadenine derivatives.
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
US8703754B2 (en) * 2010-02-10 2014-04-22 Glaxosmithkline Llc 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012092552A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
CA2826295C (en) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
LT2734186T (en) 2011-07-22 2018-12-10 Glaxosmithkline Llc Composition
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9428512B2 (en) 2012-11-20 2016-08-30 Glaxosmithkline Llc Compounds
HUE13857477T2 (en) 2012-11-20 2018-05-28 Glaxosmithkline Llc Novel compounds
ES2632448T3 (en) 2012-11-20 2017-09-13 Glaxosmithkline Llc New compounds
US10202386B2 (en) 2014-02-20 2019-02-12 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-D]pyrimidine derivatives as inducers of human interferon

Similar Documents

Publication Publication Date Title
AU2016202513A1 (en) Composition
AU2011903360A0 (en) Composition
AU2011902893A0 (en) New composition
AU2011100483A4 (en) EvacApp
AU2011100317A4 (en) SecureShred
AU2011100311A4 (en) GiftInACard
AU2011100245A4 (en) Prochute
AU2011100090A4 (en) Alcotagz
AU2011100047A4 (en) Memoriade
AU2011903028A0 (en) Picksense
AU2011902976A0 (en) Durawall
AU2011902993A0 (en) Erectabloc
AU2011902966A0 (en) Bake-it-perfect
AU2011902942A0 (en) M-Post
AU2011902846A0 (en) WonkyBall
AU2011902772A0 (en) Keypal
AU2011902747A0 (en) SharpsCaddy
AU2011902674A0 (en) Vandewiel
AU2011902553A0 (en) Vidunce
AU2011902452A0 (en) Wiking rollavator
AU2011902361A0 (en) Hammers-extended
AU2011902357A0 (en) Bm2go
AU2011901967A0 (en) ComfortAll
AU2011901850A0 (en) Acrodrome
AU2011901678A0 (en) Rumentek